💥 Meet Ricardo, the energy powerhouse behind our sales teams in LAPAC and LATAM! In the fourth episode of our Faces of SOPHiA GENETICS video series, we spotlight Ricardo Ramos Mendonca Filho, our Managing Director, LAPAC. Leading a team of 12 and managing relationships with over 150 customers, Ricardo’s positive attitude and genuine care for his team and clients shine through every day. What we love about Ricardo is that, for him, customers are more than clients—they’re partners on a shared journey towards success. His dedication and collaborative spirit drive us all forward with a united vision for the future. 🎥 Watch the full episode and discover what makes life at SOPHiA GENETICS so special. Follow our LinkedIn page for more inspiring stories! #FacesOfSOPHiAGENETICS #Teamwork #Inspiration #DataDrivenMedicine
SOPHiA GENETICS
Biotechnologieforschung
Democratizing Data-Driven Medicine, Together!
Info
SOPHiA GENETICS is the creator of SOPHiA DDM™, a cloud-based platform capable of analyzing data and generating insights from complex multimodal data sets and different modalities. The SOPHiA DDM™ Platform enables healthcare institutions to get quick, robust insights from their data. We apply our technology to areas such as cancer and inherited disorders, where combining genomic and phenotypic information is vital to support research and drug development efforts. SOPHiA GENETICS' data-sharing methodology also helps researchers and healthcare professionals work together as a community by sharing and leveraging patterns identified via artificial intelligence and machine learning. Our universal platform is designed to improve as we analyze more data over time. The SOPHiA DDM™ Platform is one of the largest technology-agnostic networks of connected healthcare institutions worldwide and is currently used by more than 750 hospital, laboratory, and biopharma institutions globally. ___________ SOPHiA GENETICS Community Guidelines We value the insights and perspectives of all our members. To ensure a constructive environment, we kindly ask everyone to adhere to the following guidelines: - Respectful interactions: treat everyone with respect and courtesy. - Constructive sharing: contribute comments and ideas that are relevant and add value to the conversation. - Stay on-topic: ensure your comments are relevant to the post or discussion. - Avoid inappropriate content: refrain from posting content that is unethical, hateful, offensive, speculations about our stock prices or financial discussions that are not in the scope of the social media platform. - No spam or solicitations: for business inquiries or other topics, kindly use the 'Contact Us' section on our official website. - Moderation rights: we reserve the right to remove comments that do not align with our guidelines, principles and values. By participating in our community, you agree to these guidelines.
- Website
-
http://www.sophiagenetics.com/
Externer Link zu SOPHiA GENETICS
- Branche
- Biotechnologieforschung
- Größe
- 201–500 Beschäftigte
- Hauptsitz
- Rolle
- Art
- Privatunternehmen
- Gegründet
- 2011
- Spezialgebiete
- Bioinformatics, Algorithms, genomics, big data, clinical, artificial intelligence, AI, Machine Learning, Deep Learning, Oncology, Cancer, ctDNA, Liquid Biopsy, Data-Driven Medicine, Precision Medicine und AI in Healthcare
Orte
-
Primär
La Pièce 12
Rolle, 1180, CH
-
185 Dartmouth St
Floor 5
Boston, Massachusetts 02116, US
-
Technopole Izarbel 158 allée Fauste d’Elhuyar
Bidart, 64210, FR
Beschäftigte von SOPHiA GENETICS
Updates
-
🇬🇧 Webinar alert! Join the online interactive learning session to understand and discuss the recent changes in HRD testing for Ovarian Cancer offered by the North Thames Genomics Laboratory Hub (NTGLH). 💡 What you will learn: • Testing Changes: Detailed explanation of the changes to HRD testing for advanced ovarian cancer implemented across North Thames since December 2023. • Clinical Impact: Insights into what these changes mean for clinicians and their teams, with opportunities for questions and clarifications. • New Reporting System: Overview of the changes to the HRD report and scoring system, including template examples and where to find key information. • Validation and Confidence: Discussion on the validation work done before the test went live, comparison of all 4 assays, and review of clinical data from SOPHiA GENETICS. • Open Discussion: Engage in an open table discussion around all aspects of the new service, addressing specific requirements and differences in the new HRD reports. Why Attend? ↳ NICE Guidelines Compliance: Understand how to comply with NICE guidelines recommending genomic testing for HRD in patients with ovarian, breast, and prostate cancer to identify eligibility for PARP inhibitors treatment. ↳ Enhanced Understanding: Gain a comprehensive understanding of the HRD send-away service and its specific requirements. ↳ Expert Insights: Benefit from the expertise of leading professionals in the field, ask questions, and clarify any doubts regarding the new HRD testing service. 🔗 Register now: https://loom.ly/wa9sUv4 #HRD #Webinar #OvarianCancer #Oncology #NHS NHS North Thames Genomic Medicine Service The Royal Marsden NHS Foundation Trust
-
-
📣 Exciting News: OncoHelix, an internationally recognized research and diagnostics laboratory for precision diagnostics based in Canada, is the first laboratory in Canada to adopt MSK-ACCESS® powered with SOPHiA DDM™. “Our mission at OncoHelix is to offer exceptional clinical-grade molecular and immune profile testing. That mission is predicated on using the most cutting-edge technology,” said Dr. Pinaki Bose, Co-founder and Executive Vice President, OncoHelix. “MSK-ACCESS® powered with SOPHiA DDM™ marks a major advancement in cancer genomic profiling using circulating free DNA and enhances our ability to gain insights from cancers when tissue biopsy is unavailable,” notes Dr. Faisal Masood Khan, Co-founder and CEO at OncoHelix. OncoHelix currently uses the SOPHiA DDM™ Platform for myeloid testing. “We are excited to expand our relationship with OncoHelix by offering this new liquid biopsy solution and continue supporting the company’s commitment to tackling cancer research.” said John Carey, MBA, Managing Director, NORAM, SOPHiA GENETICS. 🔗 Read the full press release: https://loom.ly/fpFDTS0 #DataDrivenMedicine #PrecisionMedicine #Oncology #LiquidBiopsy #PressRelease #Media
-
💡 Read our latest Poster Spotlight, hosting The Royal Marsden NHS Foundation Trust Clinical Genomics team: "The Validation of a Homologous Recombination Deficiency Assay into Clinical Practice within the NHS". 💬 In this piece, we talked to the two presenters of the poster Elizabeth Ratsma, Pre-Registration Clinical Scientist – Cancer Genomics and Charlotte Flanagan, PhD, Innovation Lead, from The Royal Marsden NHS Foundation Trust. We discussed the scope and outcomes of this study, as well as the The Royal Marsden NHS Foundation Trust's experience with implementing the SOPHiA DDM™ GIInger Genomic Integrity Solution. 📄The poster was recently presented at the ESMO - European Society for Medical Oncology Gynaecological Cancers Congress 2024 in Florence, Italy. 🔗 Read the full spotlight: https://loom.ly/6F2dC4k #HRD #genomics #oncology #NHS #TheRoyalMarsden #ESMO2024 #ESMOGyn2024 #ESMO
-
-
Measurable residual disease (MRD) assessment has been established as a strong prognostic marker in AML*. Cytomorphology assays may not detect MRD at low levels. Molecular MRD assays are more sensitive, but not all MRD tests are the same. Next-generation sequencing provides the sensitivity needed to identify multiple mutations simultaneously and can detect the emergence of sub-clonal populations that can evolve over the disease course. 🔍 Download our infographic to explore the complete MRD story, learning about molecular MRD test methods and why not all tests are the same: https://lnkd.in/dMuYrT8s #MRD #CancerGenomics #NGS #Oncology *Reference: N.J., Zhou, S., Fu, C. et al. JAMA. 2020; 6(12): 1890-1899
-
Save the Date 📅 Tuesday, August 6, 2024 Get ready to dive into SOPHiA GENETICS' Q2 2024 earnings call. Join us from 8:00am - 9:00am EDT / 2:00pm - 3:00pm CET as we reveal our financial results and discuss our achievements and future plans. 🔗 Tune in live on our Investor Relations site: https://loom.ly/tux1_Jg. A replay will be available for those who want to catch up later. Mark your calendars and stay tuned for more updates! #EarningsCall #DataDrivenMedicine #Press #Media #Investors
-
-
SOPHiA GENETICS hat dies direkt geteilt
I'm excited to share my latest article on leading with passion for innovation at SOPHiA GENETICS, where our customer-centric approach drives everything we do. Thank you to our customers, partners, and dedicated team — together, we're transforming the future of healthcare. Read the full article and share your thoughts! #AIforHealthcare #DataDrivenMedicine
-
#ESMO2024 Topic Takeover 🎯 Find the right patients, for the right trials with SOPHiA DDM™ Trial Match! Explore real-world data from our vast network to enhance your clinical trials on a global scale. Improve site selection, identify the right biomarkers and patient populations, and shorten enrolment timelines, with on-demand access to the SOPHiA DDM™ Platform. Get more out of ESMO 2024 and book a meeting with us to learn how SOPHiA DDM™ Trial Match can help you accelerate clinical trial enrolment: 🔗 https://loom.ly/3pG0cZA #PrecisionOncology #PrecisionMedicine #AIforHealthcare #ClinicalTrials #Genomics #DataDrivenMedicine
-
-
🇨🇦 Our recent workshop at the The Michener Institute of Education at UHN was a success! We had the pleasure of conducting a hands-on workshop on the combined workflow of SOPHiA DDM™ and Alamut™ Visual Plus. During their final week of the course, soon-to-be-certified lab technologists from Michener attended this engaging session. Featuring a hybrid format, Simon Alfred and Emmanuel Roy led the workshop onsite, and Swati Tomar, Ph.D. remotely. This marks our second year running the workshop, and we hope to continue this tradition. Students shared their positive feedback through a survey, highlighting the value of practical experience in mastering our solutions. ✅ In the survey, an impressive number of students confirmed they would highly recommend SOPHiA GENETICS to other laboratories. We are thrilled to support the next generation of lab technologists and look forward to future collaborations! #DataDrivenMedicine #Genomics #LabTechnologists #MichenerInstitute #HealthcareInnovation
-
-
📢 Our July social media newsletter is here! 🌞 From groundbreaking partnerships and innovative solutions to inspiring events, we’ve got it all covered. Don’t miss the insightful post by Jurgi Camblong, SOPHiA GENETICS' CEO & Co-founder, about our new partnership in the Basque Country. Enjoy our full LinkedIn newsletter and share it with your network. #DataDrivenMedicine #Innovation #PrecisionMedicine #HealthcareInnovation #Newsletter
Our July Newsletter
SOPHiA GENETICS auf LinkedIn
Ähnliche Seiten
Finanzierung
Letzte Runde
Fremdkapital nach Börsengang15.000.000,00 $
Investor:innen